title: [Immunohistochemical assessment of HER2 expression in gastric cancer. A clinicopathologic study of 93 cases].
abstract: BACKGROUND
  Gastric cancer in Mexico is ranked third in both males and females. Most patients present clinically with advanced disease and treatment options are sparse. HER2 overexpression in gastric cancer is related to poor outcome. Immunohistochemical testing for HER2 is becoming the standard of care for guiding adjuvant treatment of gastric cancer with trastuzumab.
  
  
  OBJECTIVE
  To determine the frequency of HER2 overexpression in patients with gastric cancer in the Hospital de Oncología del Centro Médico Nacional, Siglo XXI and its association with other histopathological findings.
  
  
  METHODS
  Patients with gastric cancer who underwent surgery between March 12, 2006-August 31, 2011, were enrolled in this retrospective study. Diagnosis was confirmed by review of slides and immunohistochemistry with anti-HER2 antibody was performed. Scoring was done by Hoffman scoring system. Medical records were evaluated.
  
  
  RESULTS
  Ninety-three patients were included in the study, with 43 (46.2%) male and 50 (53.7%) female patients. The median age was 64 years. HER2-positive tumours were identified in 6 patients (6.45%) and located most frequently in the proximal stomach. There was no difference in HER2 overexpression in relation to age, gender or histologic type.
  
  
  CONCLUSIONS
  In our study, about 7% of patients with gastric cancer were HER2-positive on immunohistochemistry.
authors.affiliation: Departamento de Anatomía Patológica, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México. Electronic address: keme2.tijax12@gmail.com.
authors.forename: Isabel
authors.initials: I
authors.lastname: Alvarado-Cabrero
authors.affiliation: Departamento de Anatomía Patológica, Universidad de Antioquia, Medellín, Colombia.
authors.forename: Sara
authors.initials: S
authors.lastname: Gil-Hernández
authors.affiliation: Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
authors.forename: Ana
authors.initials: A
authors.lastname: Ruelas-Perea
authors.affiliation: Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
authors.forename: Diego
authors.initials: D
authors.lastname: Villaverde-Rodríguez
authors.affiliation: Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
authors.forename: José Roberto
authors.initials: JR
authors.lastname: Montes-Ochoa
authors.affiliation: Servicio de Sarcomas y Tubo Digestivo Alto, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
authors.forename: Rafael
authors.initials: R
authors.lastname: Medrano-Guzmán
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000473:pathology; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis*; D002454:Cell Differentiation; D003430:Cross-Sectional Studies; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008565:Membrane Proteins / Q000032:analysis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000276:immunology; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000473:pathology; D046888:Tissue Array Analysis
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Adenocarcinoma; Cáncer gástrico; Expresión de HER2; Gastric cancer; HER2 expression